Raquel Duarte
A5007626483- Tuberculosis Research and Epidemiology
- Infectious Diseases and Tuberculosis
- Diagnosis and treatment of tuberculosis
- Pneumocystis jirovecii pneumonia detection and treatment
- Mycobacterium research and diagnosis
- Pneumonia and Respiratory Infections
- HIV/AIDS Impact and Responses
- HIV/AIDS drug development and treatment
- COVID-19 and Mental Health
- COVID-19 Clinical Research Studies
- Immunodeficiency and Autoimmune Disorders
- Asthma and respiratory diseases
- Rheumatoid Arthritis Research and Therapies
- Sarcoidosis and Beryllium Toxicity Research
- HIV/AIDS Research and Interventions
- COVID-19 epidemiological studies
- COVID-19 Pandemic Impacts
- Dialysis and Renal Disease Management
- Drug-Induced Adverse Reactions
- Global Health and Epidemiology
- HIV Research and Treatment
- Chronic Kidney Disease and Diabetes
- Migration, Health and Trauma
- SARS-CoV-2 and COVID-19 Research
- Cardiac Imaging and Diagnostics
Universidade do Porto
2016-2025
i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto
2015-2025
Administração Regional de Saúde do Norte IP
2021-2025
Instituto de Saúde
2011-2025
Bank of Spain
2025
National Institute of Health Dr. Ricardo Jorge
2011-2025
Ricardo (United Kingdom)
2025
Instituto Nacional de Saúde
2025
Centro Hospitalar de Vila Nova de Gaia
2015-2024
University of the Witwatersrand
2012-2024
Tuberculosis control relies on the identification and preventive treatment of individuals who are latently infected with Mycobacterium tuberculosis . However, direct latent infection is not possible. The diagnostic tests used to identify M. , in vivo tuberculin skin test ex interferon-γ release assays (IGRAs), designed an adaptive immune response against, but necessarily a with, proportion truly remain after or IGRA conversion unknown. It also uncertain how long responses towards...
Anti-tumour necrosis factor (TNF) monoclonal antibodies or soluble TNF receptors have become an invaluable treatment against chronic inflammatory diseases, such as rheumatoid arthritis, bowel disease and psoriasis. Individuals who are treated with antagonists at increased risk of reactivating latent infections, especially tuberculosis (TB). Following antagonist therapy, the relative for TB is up to 25 times, depending on clinical setting used. Interferon-γ release assays or, alternative in...
Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionGood Practices for Treati...Treatment MDR-TB, Numb...Drugs and Drug ClassesBuilding a Treatment Regi...Role Therapeutic ...Shorter-Course, Standardi...Role Surgery in MDR-TBTreatment Isoniazid-Re...Treatment MDR-TB Sp...Treatment Contacts Exp...Summary Key Difference...ReferencesCITING ARTICLES
Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed evaluate the safety effectiveness of bedaquiline-containing regimens in a large, retrospective, observational conducted 25 centres 15 countries five continents.428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). admitted hospital for median (interquartile range (IQR)) 179 (92-280) days exposed 168...
In the absence of active tuberculosis, a positive tuberculin skin test (TST) or interferon-γ release assay (IGRA) result defines latent infection with Mycobacterium although results may vary depending on immunodeficiency.This study compared performance TST and IGRAs in five different groups immunocompromised patients, evaluated their ability to identify those at risk for development tuberculosis.Immunocompromised patients HIV infection, chronic renal failure, rheumatoid arthritis,...
The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) management of adverse events.The aim this prospective study was to evaluate the frequency severity events anti-tuberculosis (TB) drugs in a cohort consecutive TB patients treated with new (i.e. bedaquiline, delamanid) repurposed clofazimine, linezolid) drugs, based WHO aDSM project. Adverse were collected prospectively after attribution...
BACKGROUND: Increasing evidence suggests that post-TB lung disease (PTLD) causes significant morbidity and mortality. The aim of these clinical standards is to provide guidance on the assessment management PTLD implementation pulmonary rehabilitation (PR).METHODS: A panel global experts in field TB care PR was identified; 62 participated a Delphi process. 5-point Likert scale used score initial ideas for after several rounds revision document approved (with 100% agreement).RESULTS: Five were...
Latent infection with Mycobacterium tuberculosis is defined by a positive IFN-γ release assay (IGRA) result in the absence of active tuberculosis. Only few, mostly monocentric studies have evaluated role IGRAs to predict development recent contacts low-incidence countries tuberculosis.To analyze IGRA results and effect preventive chemotherapy on progression rates among contacts.Results from contact investigations at 26 centers 10 European including testing for latent M. QuantiFERON-TB Gold...
Drug-resistant Mycobacterium tuberculosis is challenging elimination of (TB). We evaluated risk factors for TB and levels second-line drug resistance in M. patients Europe with multidrug-resistant (MDR) TB. A total 380 MDR 376 non-MDR were enrolled at 23 centers 16 countries during 2010-2011. 52.4% had never been treated TB, which suggests primary transmission tuberculosis. At initiation treatment 59.7% strains tested resistant to pyrazinamide, 51.1% ≥1 drug, 26.6% injectable drugs, 17.6%...
Despite being a preventable and curable disease, tuberculosis (TB) is still major global health threat the second leading cause of death due to an infectious agent worldwide. All efforts invested end TB have resulted overall in rather slow decreases incidence mortality rates, which been further negatively affected by ongoing coronavirus disease 2019 (COVID-19) pandemic. While majority targets End Strategy remain off track, we not yet overcome disruptions caused COVID-19 pandemic, recent...
ObjectivesAlthough evidence is growing on the overall impact of COVID-19 pandemic tuberculosis (TB) services, global studies based national data are needed to better quantify extent and countries' preparedness tackle two diseases. The aim this study was compare number people with new diagnoses or recurrence TB disease, drug-resistant (DR)-TB, deaths in 2020 vs 2019 11 countries Europe, Northern America, Australia.MethodsTB managers directors reference centers selected provided agreed-upon...
No evidence exists on tuberculosis (TB) and latent TB infection (LTBI) management policies among refugees in European countries.A questionnaire investigating screening practices was sent to 38 national programme representatives of low intermediate incidence countries/territories the WHO Region.Out 36 responding countries, 31 (86.1%) reported for active TB, 19 LTBI, eight (22.2%) reporting outcomes LTBI treatment. Screening is based algorithms including different combinations symptom-based...
The International Standards for Tuberculosis Care define the essential level of care managing patients who have or are presumed to tuberculosis, at increased risk developing disease. resources and capacity in European Union (EU) Economic Area permit higher standards secure quality timely TB diagnosis, prevention treatment. On this basis, (ESTC) were published 2012 as specifically tailored EU setting. Since publication ESTC, new scientific evidence has become available and, therefore,...